No Data
Guosen: AI technology drives precise diagnosis to achieve important breakthroughs.
The combination of AI and multi-omics is revolutionizing the fields of biomedicine and data science.
Can Mixed Fundamentals Have A Negative Impact on Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Current Share Price Momentum?
Guangzhou LBP Medicine Science & Technology (688393.SH): The research and development layout in the field of pathological digital intelligence includes pathological AI and the construction of pathological large models.
On March 7, Gelonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) stated on the interaction platform that the company is currently not integrated with DeepSeek. The company's research and deployment in the field of pathological digital intelligence includes pathological AI and the construction of large pathological models. The core of pathological AI is the construction of visual models, while large pathological models require the integration of multimodal models such as language models and visual models. We are evaluating and testing several open-source language models in the medical field (including DeepSeek), and if they meet internal acceptance criteria, they will be applied to the pathological digital intelligence business platform.
Anbiping: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
Guangzhou LBP Medicine Science & Technology (688393.SH): In 2024, the net income is 22.0369 million yuan, a year-on-year decrease of 44.99%.
On February 25, Glonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) announced its performance report for the fiscal year 2024. During the reporting period, the company achieved revenue of 470.7901 million yuan, a decrease of 5.33% year-on-year; it recorded a Net income of 22.0369 million yuan, down 44.99% year-on-year; the Net income attributable to the parent company, excluding non-recurring gains and losses, was 13.7024 million yuan, representing a decline of 61.20% year-on-year; as of the end of the reporting period, total Assets were 1364.4001 million yuan, down 2.54% compared to the beginning of the reporting period; equity attributable to the parent company.
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%